OraSure Q1 Revenue Falls 7% on Weak HCV Sales, Operating Income Misses Estimates
Summary
OraSure Technologies reported a 7% year-over-year decline in Q1 revenue to $27.9 million, primarily driven by lower HCV test sales. While the company slightly beat revenue consensus estimates, it missed adjusted operating income expectations, reporting a -$19 million loss against a -$15.86 million consensus. This continues a trend of revenue contraction, following a significant 38% decline in fiscal year 2025. Despite these challenges, gross margin improved to 42.3%, and the company repurchased $5 million in stock. OraSure provided Q2 2026 revenue guidance of $27 million to $30 million, indicating continued pressure. Traders will be watching for signs of stabilization in core diagnostics sales and the impact of efficiency initiatives.
At the time of this announcement, OSUR was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $215.9M. The 52-week trading range was $2.08 to $3.82. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.